BOOST Pharma raises €3.1M for rare disease therapeutics

Europe’s rare disease pharmaceutical sector is experiencing renewed investor confidence, with regulatory frameworks like the EU Orphan Drug Regulation creating compelling opportunities for specialised therapeutics. Swedish biotech BOOST Pharma has secured an additional €3.1 million in funding to advance treatments for children with genetic bone diseases, highlighting the growing appetite for precision medicine targeting underserved patient populations. Sound Bioventures led this follow-on round, demonstrating continued conviction in BOOST Pharma’s approach to rare paediatric conditions. The investment builds on previous backing and positions the Stockholm-based company to accelerate clinical development programmes. Rare disease biotech funding gains momentum in Europe Sound Bioventures’ investment thesis centres on therapeutic areas with high unmet medical need and clear regulatory pathways. The fund, known for backing European life sciences companies with differentiated platforms, sees particular value in BOOST Pharma’s focus on genetic bone disorders affecting children. “We’re backing a team that understands both the scientific complexity of rare bone diseases and the commercial realities of developing orphan drugs in Europe,” explained a Sound Bioventures partner. The investor’s portfolio strategy emphasises companies that can navigate EU regulatory frameworks whilst addressing global markets. This funding round reflects broader European investor confidence in rare disease therapeutics, where smaller patient populations allow for more targeted development strategies and accelerated regulatory timelines through programmes like EMA’s PRIME designation. Advancing genetic bone disease treatments BOOST Pharma’s platform addresses genetic bone disorders that predominantly affect children, representing a significant unmet medical need with limited therapeutic options. The company’s approach leverages advanced understanding of bone biology to develop targeted interventions for these rare conditions. The €3.1 million will primarily fund clinical trials and regulatory preparation activities across European markets. BOOST Pharma plans to initiate patient studies whilst building manufacturing capabilities to support future commercial deployment. “Children with genetic bone diseases and their families deserve better treatment options,” stated BOOST Pharma’s leadership team. “This funding enables us to advance our lead programmes through critical development milestones whilst maintaining our European operational base.” The company’s Stockholm headquarters provides access to Scandinavian clinical networks and regulatory expertise, whilst maintaining cost advantages compared to other European biotech hubs. Recent data from European rare disease registries suggests growing recognition of genetic bone disorders, creating clearer commercial pathways for specialised therapeutics. This investment signals Sound Bioventures’ confidence in Europe’s rare disease ecosystem and BOOST Pharma’s potential to deliver meaningful outcomes for underserved patient populations through precision therapeutic approaches.

Controlled environment agriculture is experiencing unprecedented investment momentum across Europe, driven by supply chain resilience concerns and sustainability mandates. The latest beneficiary of this sector surge is Source.ag, which has secured €16.1M ($17.5M) in Series B funding to accelerate its AI-powered solutions for indoor farming operations. The round positions Source.ag among Europe’s most well-capitalised agtech platforms, enabling the company to expand its data-driven approach to crop optimisation across multiple European markets. With food security climbing political agendas and vertical farming installations proliferating, this funding arrives at a pivotal moment for the sector. Astanor Ventures leads agtech funding expansion Astanor Ventures, the Brussels-based investment firm focused exclusively on food and agriculture technology, led the Series B round with participation from several unnamed co-investors. The firm’s decision reflects a broader thesis around data-driven agriculture solutions that can address Europe’s growing demand for locally-produced, pesticide-free crops. “The convergence of AI capabilities and controlled environment agriculture represents a fundamental shift in how Europe approaches food production,” noted an Astanor partner familiar with the investment. “Source.ag’s platform addresses the operational complexity that has historically limited scalability in indoor farming.” Astanor’s involvement signals confidence in Source.ag’s ability to navigate the fragmented European market, where regulatory frameworks vary significantly between member states. The firm’s portfolio includes several companies tackling adjacent challenges in sustainable agriculture, creating potential synergies for cross-portfolio collaboration. AI-driven agriculture gains European traction Source.ag’s platform combines machine learning algorithms with environmental sensors to optimise growing conditions in controlled environments such as greenhouses and vertical farms. The technology addresses critical pain points including energy efficiency, crop yield prediction, and resource allocation – challenges that become more acute as operations scale. The funding will primarily support expansion across Germany, Netherlands, and Scandinavia, regions where controlled environment agriculture adoption is accelerating due to climate constraints and consumer demand for year-round local produce. Source.ag plans to establish regional partnerships with equipment manufacturers and facility operators. “European growers face unique challenges compared to their North American counterparts, particularly around energy costs and regulatory compliance,” explained Source.ag’s management team. “Our platform is designed specifically for European operational realities, from carbon reporting requirements to varying labour regulations.” The Series B funding brings Source.ag’s total capital raised to approximately €25M, positioning the company to compete with established players like Priva and emerging platforms such as InFarm in the rapidly consolidating agtech landscape. This investment underscores Europe’s growing appetite for agricultural technology solutions that can deliver measurable sustainability outcomes whilst maintaining commercial viability. As controlled environment agriculture transitions from niche applications to mainstream food production, data-driven platforms like Source.ag are becoming essential infrastructure for the sector’s continued evolution.

The European digital health sector is experiencing unprecedented growth, driven by rising healthcare costs and an ageing population seeking accessible treatment solutions. With over 800 million people worldwide living with obesity, the market for digital therapeutic interventions has become increasingly attractive to investors. Warsaw-based Holi has capitalised on this trend, securing €3 million in seed funding to expand its digital treatment platform across Europe. The round was led by 4growth VC, a Warsaw-based venture capital firm known for backing early-stage European healthtech companies. This investment represents a strategic bet on the growing digital therapeutics market, where traditional pharmaceutical approaches are being complemented by technology-driven solutions. Seed funding strengthens digital obesity treatment expansion 4growth VC’s decision to lead this round reflects their thesis on digital health disruption in Central and Eastern Europe. The firm has been particularly active in backing companies that address chronic disease management through technology, viewing the obesity treatment market as significantly underserved by traditional healthcare systems. “We see tremendous potential in Holi’s approach to combining clinical expertise with digital delivery,” said a spokesperson from 4growth VC. “The obesity epidemic requires scalable solutions that can reach patients beyond traditional clinical settings, and Holi’s platform addresses this need directly.” The investment comes at a time when European regulators are increasingly supportive of digital therapeutic solutions. Recent EU medical device regulations have created clearer pathways for digital health platforms to gain regulatory approval, providing companies like Holi with greater market certainty. Platform targets underserved European obesity market Holi’s digital platform differentiates itself in the European market by focusing specifically on obesity treatment through a combination of behavioural therapy, nutrition guidance, and clinical oversight. Unlike many generic wellness apps, Holi’s approach is grounded in clinical methodology and designed to work within existing healthcare systems. The company plans to use the €3 million funding to expand beyond Poland into other European markets, where obesity rates continue to climb despite traditional treatment approaches proving insufficient. The platform’s digital-first model allows it to overcome geographical barriers that limit access to specialist obesity treatment centres. “Our goal is to make evidence-based obesity treatment accessible across Europe,” explained Holi’s founding team. “Traditional approaches often fail because they don’t provide the ongoing support and behavioural change tools that patients need for long-term success.” The funding will also support clinical trials necessary for broader European regulatory approval and integration with national healthcare systems. This represents a critical step for digital therapeutics companies seeking to move beyond consumer-pay models to insurance-reimbursed treatments. This investment signals growing confidence in European digital therapeutics, particularly for chronic conditions that require long-term management. With healthcare systems across Europe struggling with rising obesity-related costs, solutions like Holi’s may prove essential for sustainable healthcare delivery.